Defunct Company
Total Trials
9
As Lead Sponsor
6
As Collaborator
3
Total Enrollment
5,390
NCT01399502
Promotion of Self-help Strategies for Depression
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 30, 2011
Completion: Dec 31, 2012
NCT02070211
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
Phase: Phase 2/3
Role: Collaborator
Start: Jun 30, 2014
Completion: Jun 30, 2016
NCT02751632
The Staged Treatment in Early Psychosis Study
Phase: Phase 3
Start: Apr 30, 2016
Completion: May 31, 2022
NCT05905003
AMP SCZ® Observational Study: PREDICT-DPACC
Phase: N/A
Start: Jun 2, 2022
Completion: May 31, 2025
NCT05957848
Guanfacine Extended-release for Adolescents With Cannabis Use
Phase: Phase 2
Start: Jul 27, 2023
Completion: Jun 30, 2026
NCT06364332
Chatsafe Netherlands: Improving Safe Suicide Communication for Young People on Social Media
Start: Apr 8, 2024
Completion: Mar 31, 2025
NCT06463470
Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
Start: Jun 27, 2024
Completion: Jun 27, 2027
NCT06894836
Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety
Start: Apr 1, 2025
Completion: Oct 1, 2026
NCT07114887
Virtual Reality for Vocational Recovery
Start: Aug 31, 2025
Completion: Dec 31, 2025